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Abstract 
Obesity caused by the consumption of a high-fat (HF) diet is a major risk factor for the development of 
associated complications, such as heart and kidney failure. A semi-synthetic triterpenoid, bardoxolone 
methyl (BM) was administrated to mice fed a HF diet for 21 weeks to determine if it would prevent the 
development of obesity-associated cardiac and renal pathophysiologies. Twelve week old male C57BL/6J 
mice were fed a lab chow (LC), HF (40% fat), or a HF diet supplemented with 10 mg/kg/day BM in drinking 
water. After 21 weeks, the left ventricles of hearts and cortex of kidneys of mice were collected for 
analysis. Histological analysis revealed that BM prevented HF diet-induced development of structural 
changes in the heart and kidneys. BM prevented HF diet-induced decreases in myocyte number in cardiac 
tissue, although this treatment also elevated cardiac endothelin signalling molecules. In the kidneys, BM 
administration prevented HF diet-induced renal corpuscle hypertrophy and attenuated endothelin 
signalling. Furthermore, in both the hearts and kidneys of mice fed a HF diet, BM administration prevented 
HF diet-induced increases in fat accumulation, macrophage infiltration and tumour necrosis factor alpha 
(TNFα) gene expression. These findings suggest that BM prevents HF diet-induced developments of 
cardiac and renal pathophysiologies in mice fed a chronic HF diet by preventing inflammation. Moreover, 
these results suggest that BM has the potential as a therapeutic for preventing obesity-induced cardiac 
and renal pathophysiologies. 
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Abstract  
Obesity caused by consumption of a high-fat (HF) diet is a major risk factor for the development 
of associated complications, such as heart and kidney failure. A novel semi-synthetic triterpenoid, 
bardoxolone methyl (BM) was administrated to mice fed a high-fat (HF) diet for 21 weeks to 
determine if it would prevent the development of obesity-associated cardiac and renal 
pathophysiologies. Twelve week old male C57BL/6J mice were fed a lab chow (LC), HF (40% 
fat), or a HF diet supplemented with 10 mg/kg/day BM in drinking water. After 21 weeks, the left 
ventricles of hearts and cortex of kidneys of mice were collected for analysis. Inflammatory and 
endothelin signalling molecules were examined in heart and kidney tissue using 
immunohistochemistry and RT-PCR. Histological analysis revealed that BM prevented HF diet-
induced development of structural changes in the heart and kidneys. BM prevented HF diet-
induced decreases in myocyte number in cardiac tissue and renal corpuscle hypertrophy in the 
kidney. Furthermore, in both the hearts and kidneys of mice fed a HF diet, BM administration 
prevented HF diet-induced increases in fat accumulation, macrophage infiltration and TNFα gene 
expression. These findings suggest that BM prevents HF diet-induced developments of cardiac 
and renal pathophysiologies in mice fed a chronic HF diet by preventing inflammation. Moreover, 
these results suggest that BM has the potential as a novel therapeutic for preventing obesity-
induced cardiac and renal pathophysiologies 
  
 
1. Introduction 
Obesity caused by the consumption of a high-fat (HF) diet increases the risk of cardiorenal 
diseases. Cardiovascular disease is the leading cause of death worldwide, with the incidence 
expected to rise from 17.3 million per year in 2008 to over 23.6 million per year by 2030 
(Mozaffarian, Benjamin et al. 2015). There is increasing evidence that obese individuals have an 
increased risk of developing cardiovascular disease (Kenchaiah, Evans et al. 2002). In addition, 
there is direct evidence that obesity from a HF diet can cause kidney injury, which also increases 
the associated cardiovascular disease risk (Prasad 2014). Therefore, there is an urgent need to 
find suitable therapeutics that can prevent HF diet-induced obesity-associated complications to 
the heart and kidney, in order to reduce the incidence of global mortality from cardiorenal 
disease. 
The endothelin system has been suggested to play an important role in the development of 
cardiovascular pathophysiologies. In the heart, endothelin 1 (ET-1) acts through two receptors, 
endothelin receptor type a (ETA) and endothelin receptor type b (ETB). The key endothelin system 
molecules ET-1, ETA and ETB play a role in vasoconstriction, with ETB also having an additional 
role in vasodilation (Kedzierski and Yanagisawa 2001). In the cardiac muscle, ET-1 activates ETA 
which results in the promotion of cardiac hypertrophy leading to subsequent heart failure (Nasser 
and El-Mas 2014). Previous studies have demonstrated that there is therapeutic potential in 
targeting the endothelin system with ETA or combined ETA/ETB antagonists in patients with 
congestive heart failure (Krum, Viskoper et al. 1998, Nakov, Pfarr et al. 2002). However, it is 
important to note that in the kidneys the endothelin pathway plays several important roles 
including the regulation of sodium and water homeostasis and renal blood flow (Kohan 2006). 
Therefore, over-suppression of the endothelin pathway by antagonistic drugs may lead to other 
complications in the kidneys such as fluid retention, which if not addressed can also lead to heart 
 
failure (Kohan 2006). Therefore, the development of therapeutics that appropriately targets the 
endothelin pathway in the heart and kidneys is warranted, in order to prevent obesity-associated 
cardiovascular disease and renal failure. 
Obesity from HF diet is known to result in the development of fat accumulation in peripheral 
organs, such as the heart and kidneys (Montani, Carroll et al. 2004). Furthermore, peripheral fat 
accumulation is associated with macrophage infiltration into adipose tissue, which promotes the 
release of proinflammatory cytokines including tumour necrosis factor alpha (TNFα) (Wellen and 
Hotamisligil 2005). In a recent study, significantly higher levels of inflammatory markers, including 
TNFα, were found in the cardiac tissue of Tibetan mini pigs as a result of being fed a HF diet for 
24 weeks (Yongming, Zhaowei et al. 2015). Furthermore, rats fed a HF diet for 10 weeks 
demonstrated increased TNFα levels in the cortex of their kidneys (Elmarakby and Imig 2010). 
Therefore, novel pharmaceuticals that attenuate TNFα levels may provide a potential therapy for 
preventing obesity-induced inflammation and tissue damage such as to the heart and kidneys. 
In recent years, BM has been extensively studied in both preclinical rodent studies and human 
clinical trials, and shows promise for the treatment of renal diseases such as chronic kidney 
disease, and colitis-induced colon cancer due to its anti-inflammatory effects (Pergola, Krauth et 
al. 2011, Pergola, Raskin et al. 2011, de Zeeuw, Akizawa et al. 2013, Camer, Yu et al. 2014, 
Choi, Kim et al. 2014). Specifically, studies have demonstrated that BM can reduce inflammation 
induced by modulating TNFα levels in rodents fed a HF diet (Saha, Reddy et al. 2010, Dinh, 
Szabo et al. 2015). In addition, our previous studies have highlighted BM as a potential novel 
therapeutic for preventing HF diet-induced obesity, visceral fat accumulation, and associated 
development of insulin resistance, hepatic steatosis and cognitive deficits (Camer, Yu et al. 2015, 
Camer, Yu et al. 2015, Dinh, Szabo et al. 2015). However these positive findings were 
overshadowed by the recently terminated phase III human clinical trial where there were adverse 
 
cardiovascular events seen in patients with advanced chronic kidney disease treated with BM (de 
Zeeuw, Akizawa et al. 2013). The mechanisms contributing to these adverse events in the clinical 
trial were speculated to be via the modulation of the endothelin pathway (Chin, Reisman et al. 
2014). However, this pathway was not investigated in the heart tissue (Camer and Huang 2014) 
and in the kidney following chronic BM treatment, suggesting that further investigation into this 
drug was vital. In addition, the therapeutic effects of BM treatment on the hearts and kidneys of 
mice fed a chronic HF diet have not been examined previously. 
Here, we provide the first evidence that oral administration of BM prevents HF diet-induced 
cardiac hypertrophy in mice fed a chronic HF diet. In addition, the development of HF diet-
induced kidney pathophysiologies was prevented by BM administration. Specifically, BM 
administration prevented HF diet-induced macrophage infiltration and elevation of TNFα gene 
expression in the heart and kidneys of mice fed a HF diet. Furthermore, BM treatment 
suppressed endothelin signalling molecules in the kidney, but elevated expression of endothelin 
signalling molecules in the heart. These findings indicate the potential of BM as a future 
therapeutic for the prevention of obesity-related complications, such as cardiac hypertrophy and 
chronic kidney disease. 
2. Materials and Methods 
2.1 Animals and HF diet-induced obesity model 
Twelve week old C57BL/6J male mice were purchased from the Animal Resource Centre (Perth, 
Western Australia) and kept in the animal research facility at the University of Wollongong. The 
experiments were performed in accordance with the Australian Code of Practice for the Care and 
Use of Animals for Scientific Purposes. All procedures were approved by the Animal Ethics 
Committee, University of Wollongong, Wollongong, Australia (AE 12/15). Mice were housed in 
environmentally controlled conditions at a constant temperature of 22 °C with a 12 hour light/dark 
 
cycle. Following 1 week of acclimatisation, mice were randomly divided into 3 groups (n=7 per 
group). For the next 21 weeks one group of mice were fed a lab chow (LC) diet (5% of energy as 
fat; Vella Stock Feeds, Doonside, New South Wales, Australia), and the other two groups a HF 
diet (40% of energy as fat; SF11-095, Specialty Feeds, Glen Forrest, Western Australia). Mice in 
the treatment group were fed a HF diet for 21 weeks, along with a daily oral dose of BM (10 
mg/kg) in their drinking water. The dose was chosen according to a previous study (Wu, Liu et al. 
2014). Body weights of mice were measured weekly for the duration of the experiment (Final 
average body weight after 21 weeks: LC, 27.15g; HF, 40.84g; HF+BM, 28.13g).  
2.2 Tissue collection  
Mice were euthanised (n=7 per group) at week 21 of the experiment. The kidneys and heart were 
dissected from each mouse. The full hearts were weighed before the apex was cut and place in 
10% formalin. The right kidneys of each mouse were cut in half before the inferior portion was 
place into 10% formalin. The remaining heart and kidney tissue were snap frozen in liquid 
nitrogen, and stored at -80 °C until use. 
2.3 Microdissection 
Frozen heart and kidney tissue were cut into 10 μm sections with a cryostat at -18 °C before 
being mounted on Polylysine™ microscope slides for histological staining. Specifically, the apex 
of the hearts and the superior portion of the cortex of the kidney were sectioned. The left ventricle 
of each mouse heart and inferior portion of the kidney cortex were micro-dissected from 500 μm 
thick frozen sections, and collected for RT-PCR. Kidney and heart tissue were both stored at a 
temperature of -80 °C until use.  
2.4 Oil Red O staining 
Oil Red O staining was used to examine lipid accumulation in the heart and kidneys as described 
previously (Kudo, Tamagawa et al. 2007, Camer, Yu et al. 2015). Briefly, frozen heart and kidney 
 
sections (10 μm) were stained with 0.5% Oil Red O (Sigma-Aldrich) for 15 minutes and then 
washed. Three fields from three sections collected from each mouse were viewed under a Leica 
microscope, and digital photographs were captured. Image J software 
(http://imagej.nih.gov/ij/download.html) was used to quantify staining, which corresponded to the 
percentage of stained lipid droplets on an area of each slide (Mehlem, Hagberg et al. 2013).  
2.5 Haematoxylin and Eosin (H&E) staining 
Briefly, frozen kidney and heart sections (10 μm) were stained with Haematoxylin and Eosin 
(POCD Scientific, Artamon, Australia) for 30 seconds each. Three fields from three sections of 
each mouse were viewed under a Leica microscope and digital photographs captured. The 
histological parameters of glomerular and Bowman’s capsule hypertrophy in the kidneys were 
calculated according to the methods described by previous studies (Al-Douahji, Brugarolas et al. 
1999, Henegar, Bigler et al. 2001). In the heart tissue, myocytes were measured quantitatively 
using the software, Image J according to our previous study (Camer, Yu et al. 2015, Dinh, Szabo 
et al. 2015).  
2.6 Immunohistochemistry 
Immunohistochemistry was performed as described previously (Camer, Yu et al. 2015, Dinh, 
Szabo et al. 2015). Briefly, heart and kidney sections fixed in 10% formalin were embedded in 
paraffin before being sectioned (5 μm) onto Polylysine™ slides. Slides were incubated overnight 
at 4 °C with anti-rabbit F4/80, anti-goat ET-1, anti-goat ETB, or anti-rabbit ETA primary antibody 
(1:150 Santa Cruz Biotechnology, Dallas, TX) diluted in blocking buffer. Samples were then 
incubated consecutively at room temperature for 30 minutes with their respective secondary 
antibody (1:150 Santa Cruz Biotechnology, TX) and then streptavidin-HRP polymer conjugate 
(1:1000 2438, Sigma-Aldrich Pty Ltd, Sydney, Australia). A DAB peroxidise substrate kit (4100, 
Vector Laboratories Inc, Burlingame, CA) was used for the development of the stained sections 
 
before counterstaining with H&E (POCD Scientific, Artarmon, Australia). Three fields from three 
sections of each mouse were viewed under a Leica microscope and digital photographs captured. 
Image J software was used to quantify the area of F4/80, ET-1, ETA, or ETB staining in heart and 
kidney tissue on each slide.  
2.7 RNA isolation and RT-PCR 
Total RNA was extracted from dissected mouse heart and kidneys using the Aurum total RNA 
mini kit (Bio-Rad Laboratories, Hercules, CA) before being reversed transcribed to complimentary 
first strand DNA with a high-capacity cDNA reverse transcription kit (AB Applied Biosystems, 
California, USA) according to the manufacturer’s directions. Quantitative real-time PCR (RT-PCR) 
was performed using a Light cycler 480 real time PCR system (F.Hoffmann-La Roche Ltd, 
Switzerland). A 20μl final reaction volume containing cDNA sample and SYBR green I master mix 
was used for PCR Briefly, amplification was carried out with 45 cycles of 95 °C for 10 seconds, 
60 °C for 30 seconds and 72 °C for 30 seconds. The expression of mRNA was normalised to an 
internal control, GADPH. The degree of mRNA expression was calculated using the comparative 
threshold cycle value (Ct) method, using the formula 2–ΔΔCt (where ΔΔCt =ΔCt sample - ΔCt 
reference) as described previously (Camer, Yu et al. 2015, Cheng, Yu et al. 2015). The primers 
used are listed in Table 1.3.  
2.8 Statistics 
Data were analysed using the statistical package SPSS 20 (SPSS, Chicago, IL). Data was first 
tested for normality before differences between mice fed a LC diet, HF diet, or HF diet 
administered with BM diet were determined by one-way analysis of variance (ANOVA). This was 
followed by the post hoc Tukey-Kramer honestly significant difference (HSD) test for multiple 
comparisons among the groups. A p value of <0.05 was considered statistically significant. 
Values are expressed as mean ± SEM.  
 
3. Results  
3.1 Bardoxolone Methyl prevented the development of cardiac hypertrophy, fat accumulation, and 
inflammation in mice fed a high-fat diet 
To assess whether BM treatment can prevent diet-induced cardiac hypertrophy, we analysed 
heart tissue in mice fed a HF diet for 21 weeks. Following 21 weeks on a HF diet, the hearts of 
mice had significantly higher weights than mice fed a LC diet (Final heart weight: -20.66%, 
p<0.001, Figure 1A). This increase in heart weight was prevented by oral administration of BM 
(Final heart weight: -27.04%, p<0.001, Figure 1A). However, there were no significant differences 
in heart to body weight ratios between any of the groups (Figure 1B). We performed haematoxylin 
and eosin (H&E) and oil red O staining to examine the effects of BM on myocyte number and lipid 
content in the heart (Figure 1C). Histological examination of mouse hearts revealed that there 
was a significant decrease in myocyte number and significant increase in cytoplasmic lipid 
droplets in mice fed a HF diet for 21 weeks compared to LC fed mice (Myocyte count: -37.43%; 
lipid stained area: +80.12%, p<0.001, Figures 1D and 1E). This change in cardiac morphology 
was significantly attenuated by BM treatment compared to untreated mice fed a HF diet (Myocyte 
count: +28.11%; lipid stained area: -50.61%, p<0.001, Figures 1D and 1E). However, BM 
treatment failed to revert HF diet-induced alterations in myocyte number and lipid content in 
cardiac tissue to the levels present in control LC mice (Myocyte count: -12.97 %; lipid stained 
area: +59.75%, p<0.001, Figures 1D and 1E). These results suggest that cardiac hypertrophy 
and cellular lipid droplet accumulation induced by a HF diet is attenuated with BM treatment. 
To investigate the effect of BM on macrophage accumulation in the left ventricle of the heart in 
HF diet fed mice, we performed immunohistochemistry with an anti-F4/80 antibody. We found 
that macrophage numbers increased in the left ventricle of HF diet fed mice as indicated by 
accumulation of F4/80 positive cells (HF vs. LC difference: -53.17%, p<0.05, Figure 1F). BM 
 
administration significantly prevented an increase in the numbers of F4/80 positive cells in the left 
ventricle of the heart in HF diet fed mice (HF vs. BM difference: -67.40%, p<0.05, Figure 1F and 
1G). Furthermore, RT-PCR analysis showed a significant increase in TNFα and IKKβ mRNA 
expression in the left ventricle of the heart in mice fed a HF diet (HF vs. LC difference: TNFα, -
38.70%; IKKβ, -26.41%; p<0.05, Figure 1H). The alterations in TNFα mRNA levels were 
significantly prevented by BM administration (HF vs. BM difference: -63.12%, p<0.05, Figure 1H). 
However, BM treatment was unable to prevent HF diet-induced elevations in IKKβ mRNA 
expression (LC vs. BM difference: -25.47%, p<0.05, Figure 1H). No significant differences were 
found in the mRNA expression of IL-6, and IKKε between any of the groups. These results 
suggest that BM prevents the development of HF diet-induced cardiac macrophage infiltration by 
downregulating proinflammatory signalling molecules in the left ventricle of the heart. 
 
Figure 1. Bardoxolone methyl (BM) attenuated the development of cardiac hypertrophy, lipid accumulation, 
macrophage infiltration and inflammation in mice fed a chronic high-fat (HF) diet. (A) Heart weights showing 
significantly lower weights in BM treated mice compared to untreated mice fed a HF diet. (B) Heart to body weight 
ratio (HW/BW) (C) H&E and Oil Red O staining showing improved cardiac histomorphology and reduced lipid 
accumulation in mice treated with BM and fed a HF diet. Scale bar= 50μm. (D) Myocyte number per field of view. (E) 
Cardiac lipid accumulation (F and G) Histology and area of F4/80 immunoreactivity in the hearts of mice. Scale bar= 
100μm. (H) RT-PCR analysis of inflammatory genes, TNFα, IL-6, IKKβ and IKKε. *, p = <0.05 vs. lab chow (LC) 
group, #, p= <0.05 vs. HF group values are means ±SEM. (n= 7 mice per group). 
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3.2 Bardoxolone methyl prevented the development of renal corpuscle hypertrophy, fat 
accumulation and inflammation in mice fed a high-fat diet 
We evaluated whether BM treatment can prevent the development of diet-induced renal 
hypertrophy and fat accumulation in mice fed a HF diet for 21 weeks through analysis of kidney 
histomorphology. We performed haematoxylin and eosin (H&E) and oil red O staining to examine 
the effects of BM on the cellular morphology of the renal corpuscle, and lipid content in the renal 
cortex (Figure 2A). Compared to LC mice, in mice fed a HF diet for 21 weeks there was a 
significant increase in thickening of the bowman’s capsule and glomerular tuft area in the renal 
corpuscle that was coupled with a significant increase in cytoplasmic lipid droplets (Bowman’s 
capsule thickening: +91.01%; Glomerular tuft area: +41.96%; lipid stained area: +54.89%, 
p<0.001, Figures 2B-2D). This change in kidney cellular morphology was significantly attenuated 
by BM treatment compared to untreated mice fed a HF diet (Bowman’s capsule thickening: -
53.34%; Glomerular tuft area: -36.73%; lipid stained area: -56.85%, p<0.001, Figures 2B-2D). 
However, BM treatment failed to restore the thickness of the Bowman’s capsule to normal levels 
found in LC fed mice (Bowman’s capsule thickening: +80.74%, p<0.001, Figure 2B). These 
results suggest that renal corpuscle hypertrophy and cellular lipid droplet accumulation caused by 
a HF diet are attenuated with BM treatment. 
To investigate the effect of BM on macrophage accumulation in the renal cortex of HF diet fed 
mice, we performed immunohistochemistry with an anti-F4/80 antibody. We found that 
macrophage numbers increased in the renal cortex of HF diet fed mice as indicated by the 
accumulation of F4/80 positive cells (HF vs. LC difference: -52.79%, p<0.05, Figure 2E). BM 
administration prevented this increase in F4/80 positive cells (HF vs. BM difference: -46.01%, 
p<0.05, Figure 2E and 2F). Furthermore, RT-PCR analysis showed a significant increase in TNFα 
and IL-6 mRNA expression in the cortex of kidney tissue in mice fed a HF diet (HF vs. LC 
 
difference: TNFα, -66.91%; IL-6, -67.79%; p<0.05, Figure 2G). The alterations in TNFα mRNA 
levels were prevented by BM administration (HF vs. BM difference: -62.38%, p<0.05, Figure 2G). 
However, there were no significant differences in IL-6 mRNA levels between BM and the other 
groups (p>0.05, Figure 2G). No significant differences were found in the mRNA expression of 
IKKβ and IKKε between any of the groups. These results suggest that BM prevents the 
development of HF diet-induced renal macrophage infiltration by regulating proinflammatory 
signalling molecules in the cortex of the kidneys. 
 
Figure 2. Bardoxolone methyl (BM) attenuated the development of renal corpuscle hypertrophy, lipid 
accumulation, macrophage infiltration and inflammation in mice fed a chronic high-fat (HF) diet. (A) H&E and 
Oil Red O staining showing improved renal histomorphology and reduced lipid accumulation in mice treated with BM 
and fed a HF diet. Scale bar= 50μm. (B and C) Percentage of Bowman’s Capsule thickening and Glomerular Tuft 
Area demonstrating that BM administration prevented renal corpuscle hypertrophy in mice fed a HF diet (D) Renal 
lipid accumulation (E and F) Histology and area of F4/80 immunoreactivity in the kidneys of mice. Scale bar= 100μm 
(G) RT-PCR analysis of inflammatory genes, TNFα, IL-6, IKKβ and IKKε. *, p = <0.05 vs. lab chow (LC) group, #, p= 
<0.05 vs. HF group values are means ±SEM. (n= 7 mice per group). 
 
3.3 Bardoxolone methyl treatment failed to restore ETA protein expression to normal levels and 
elevated cardiac endothelin signalling genes in mice fed a high-fat diet 
Endothelin signalling proteins in the left ventricles of mouse hearts were assessed using 
immunohistochemistry in order to examine whether BM could prevent HF diet-induced increases 
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in endothelin signalling. Protein levels of ETA were significantly elevated in mice fed a HF diet 
compared to LC diet fed mice (HF vs. LC difference: -93.35%, p<0.05, Figure 3A and Table 1). 
BM treatment failed to restore HF diet-induced elevations in ETA protein to normal levels present 
in LC fed mice (BM vs. LC difference: -92.62%, p<0.05, Figure 3A and Table 1). There were no 
differences in ET-1 or ETB protein levels found between any of the groups (p>0.05, Figure 3A and 
Table 1). 
Endothelin signalling gene transcription in the left ventricle of mouse hearts were examined using 
RT-PCR. Mice fed a HF diet were found to have increased expression of the ETA gene (HF vs. 
LC difference: -45.07%, p<0.05, Figure 3B), and decreased expression of ETB gene compared to 
LC diet fed mice (HF vs. LC difference: -63.04%, p<0.05, Figure 3B). BM treatment prevented the 
HF diet-induced decrease in ETB gene expression (HF vs. BM difference: -60.62%, p<0.05, 
Figure 3B). However, BM treatment also resulted in a significant increase in ET-1 gene 
expression compared to untreated HF diet fed mice (HF vs. BM difference: -56.34%, p<0.05, 
Figure 3B). There were no significant differences in ET-1 gene expression between LC fed mice 
and mice fed a HF diet treated with BM (p>0.05, Figure 3B). Furthermore, BM administration 
elevated ETA gene expression to levels higher than both the LC fed mice and the untreated HF 
diet fed mice (LC vs. BM difference: -60.72%, p<0.05; HF vs. BM difference: -28.49%, p<0.05, 
Figure 3B). These results suggest that BM fails to restore HF diet-induced elevations of ETA 
receptor protein levels, and elevates the expression of the endothelin signalling genes, ET-1, 
ETA, and ETB in the left ventricles of mice fed a HF diet. 
 
 
Figure 3. Bardoxolone methyl (BM) elevated cardiac endothelin signalling in mice fed a chronic high-fat (HF) 
diet. (A) Cardiac ET-1, ETA and ETB proteins detected by immunohistochemistry. (B) RT-PCR analysis of cardiac ET-
1, ETA and ETB genes. *, p = <0.05 vs. lab chow (LC), #, p= <0.05 vs. HF group, values are means ±SEM. Scale 
bar= 50μm. (n= 7 per group). 
 
Table 1 Endothelin protein levels in mouse heart and kidneys following 21 weeks of LC, HF or HF + BM diet 
 Protein LC HF HF+BM F value P value 
Heart ET-1 68.0±2.8 54.4±9.7 70.4±3.9 2.101 0.193 
 ETA 0.95±0.5b 14.4±3.8a 12.9±3.1a 7.857 0.013 
 ETB 68.7±3.8 47.9±8.4 59.0±3.4 2.813 0.119 
Kidney ET-1 43.1±7.3 50.8±6.7 25.1±1.9 b 5.153 0.032 
 ETA 59.6±4.6 59.4±3.3 41.9±8.8 2.824 0.112 
 ETB 53.5±6.0 43.7±6.3 52.8±6.7 0.728 0.512 
Values are means ±SEM. LC, lab chow diet, HF, high-fat diet, HF+BM, high-fat diet and bardoxolone methyl 
treatment. ap<0.05 vs LC, bp<0.05 vs HF. 
 
  
3.4 Bardoxolone methyl treatment reduced renal endothelin signalling in mice fed a high-fat diet 
Endothelin signalling proteins in the cortex of mouse kidneys were examined using 
immunohistochemistry in order to assess if BM could prevent HF diet-induced renal dysfunction. 
There were no significant differences in the protein levels of ET-1 in HF diet fed mice compared 
to mice fed a LC diet (p>0.05, Figure 4A and Table 1). However, ET-1 protein levels were 
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significantly reduced in mice treated with BM compared to untreated mice fed a HF diet (HF vs. 
BM difference: -51.63%, p<0.05, Figure 4A and Table 1). There were no differences in ETA or ETB 
protein levels found between any of the groups (p>0.05, Figure 4A and Table 1). 
Furthermore, endothelin signalling genes in the cortex of mouse kidneys were measured using 
RT-PCR. Mice fed a HF diet were found to have increased expression of the ETA gene compared 
to LC diet fed mice (HF vs. LC difference: -49.31%, p<0.05, Figure 4B). This HF diet-induced 
increase in ETA gene expression was prevented by BM administration (HF vs. BM difference: -
46.70%, p<0.05, Figure 4B). There were no difference in ET-1 or ETB gene expression found 
between any of the groups (p>0.05, Figure 4B). These results suggest that BM prevents HF diet-
induced elevations in ETA gene expression, and significantly reduces ET-1 protein levels in the 
cortex of the kidneys of mice fed a HF diet. 
 
Figure 4. Bardoxolone methyl (BM) reduced renal endothelin signalling in mice fed a chronic high-fat (HF) 
diet. (A) Renal ET-1, ETA and ETB proteins detected by immunohistochemistry (B) RT-PCR analysis of renal ET-1, 
ETA and ETB genes. *, p = <0.05 vs. lab chow (LC), #, p= <0.05 vs. HF group, values are means ±SEM. Scale bar= 
50μm. (n= 7 per group). 
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4. Discussion 
It is well established that a HF diet can lead to the development of complications in the heart and 
kidneys, such as cardiac hypertrophy and chronic kidney disease (van Bilsen and Planavila 2014, 
Hariharan, Vellanki et al. 2015). Rodents fed a chronic HF diet have increased body weight gain, 
along with structural and functional changes in the kidneys and heart (Deji, Kume et al. 2009, 
Dhahri, Drolet et al. 2014). Previously, BM has shown promise in treating chronic kidney disease 
in phases I and II of human clinical trials via anti-inflammatory mechanisms (Pergola, Krauth et al. 
2011, Pergola, Raskin et al. 2011). Furthermore, the therapeutic benefits of BM have been 
demonstrated in HF diet-induced obese animal models such as preventing HF diet-induced 
visceral fat accumulation, insulin resistance, hepatic steatosis and recognition memory decline in 
mice (Camer, Yu et al. 2015, Camer, Yu et al. 2015, Dinh, Szabo et al. 2015). The effects of 
chronic BM administration on the prevention of renal and cardiac pathophysiologies in mice fed a 
chronic HF diet have not been examined previously. In this present study, we found that feeding a 
chronic HF diet to mice induces fat accumulation, structural changes and inflammation in the 
heart and kidneys, which was attenuated by BM administration. These results suggest that BM 
has the potential to prevent the development of renal and cardiac complications of HF diet-
induced obesity. 
There is compelling evidence that overweight or obese individuals have an increased risk of heart 
failure due to left ventricular cardiac hypertrophy (Levy, Garrison et al. 1990, Russo, Jin et al. 
2011, Barton, Baretella et al. 2012). Cardiac hypertrophy is characterised by an increase in 
myocyte size (Chien, Knowlton et al. 1991) and the activation of ET-1 (Huang, Zhang et al. 2011). 
Along with an increase in heart weight, Zucker fatty rats have an increase in ET-1, ETA and ETB 
gene expression in the left ventricle of the heart (Huang, Yang et al. 2005). In addition, mice fed a 
HF diet for 10 weeks have significantly elevated cardiac mRNA expression of ET-1, ETA and ETB 
 
genes (Catar, Muller et al. 2014). However, in dogs with congestive heart failure, inhibition of ETB 
by an antagonist resulted in increased cardiac pressure and decreased cardiac output, 
suggesting that the vasodilative actions of ETB are functionally more important than their 
vasoconstrictive actions (Wada, Tsutamoto et al. 1997). In our study, BM administration 
prevented HF diet-induced increases in myocyte size in mice, which was indicated by an increase 
in myocyte number. However, BM did not prevent HF diet-induced increases in ETA protein 
expression and worsened HF diet-induced increases in ETA and ET-1 gene expression. Despite 
this, BM prevented HF diet-induced decreases in the expression of the ETB gene. These results 
suggest that the therapeutic effects of BM on preventing HF diet-induced cardiac hypertrophy 
may be as a result of targeting the vasodilative functions of ETB, or a mechanism other than the 
endothelin pathway in the heart, such as inflammation. 
Previous studies have demonstrated that obesity can lead to the development of significant 
structural and functional changes to the kidneys that can progress to renal or even heart failure 
(Weisinger, Kempson et al. 1974, Hall, Brands et al. 1993). Obese dogs fed a HF diet were found 
to have an expansion in Bowman’s capsule area and glomerular tuft area in their kidneys 
compared to lean dogs (Henegar, Bigler et al. 2001). Our study demonstrated that chronic BM 
administration can prevent the expansion in Bowman’s capsule area and glomerular tuft area 
induced by HF diet in obese mice, suggesting BM has potential to prevent obesity associated 
kidney damage. Along with alterations in the structure and function of the kidneys, obesity 
induced by a chronic HF diet is associated with activation of the renal endothelin pathway (Barton 
2014). For example, mice fed a chronic HF diet develop obesity, which is coupled with an 
increase in mRNA expression of ETA and increased protein expression of ET-1 in the kidneys 
(Zhang, d'Uscio et al. 2001). BM has been found to suppress the renal endothelin pathway in the 
kidneys of rodents induced with chronic kidney disease by reducing the protein expression of ETA 
 
(Chin, Reisman et al. 2014). In this study, we also found that chronic BM administration 
prevented HF diet-induced increases in mRNA expression of ETA. In addition, our study 
demonstrated that BM treatment significantly decreased the protein expression of ET-1. Our 
results support findings from previous research that demonstrate that BM suppresses renal 
endothelin signalling molecules. Furthermore, our results add additional knowledge that this drug 
can also prevent HF diet induced increases in molecules involved in modulating the endothelin 
signalling pathway. 
There is extensive scientific evidence that BM can improve kidney function by inhibiting 
inflammation in a number of rodent studies and human clinical trials (Pergola, Krauth et al. 2011, 
Wu, Wang et al. 2011, Ruiz, Pergola et al. 2013). However, no study has investigated the effects 
of BM on the heart, and thus we investigated the potential preventative effects of BM on 
inflammation in the hearts and kidneys of mice fed a chronic HF diet. Along with increased fat 
accumulation, we found that there was elevated macrophage infiltration that was coupled with an 
increase in the proinflammatory TNFα gene in both the left ventricle of the heart and the cortex of 
the kidneys of mice fed a chronic HF diet. Furthermore, our results demonstrated that chronic BM 
treatment prevented HF diet-induced fat accumulation, macrophage infiltration and elevated 
TNFα gene expression in the left ventricular area of the heart and cortex of the kidneys of mice. A 
possible mechanism for these anti-inflammatory effects of BM in these regions of the heart and 
kidneys includes preventing TNFα gene expression and macrophage infiltration, resulting in the 
attenuation of the proinflammatory response and organ fat accumulation. 
In conclusion, our findings suggest that chronic supplementation with BM can prevent HF diet-
induced development of cardiac and renal pathophysiologies in mice. Since obesity-induced 
peripheral fat accumulation and inflammation has been implicated in the progression of heart 
failure, BM may have beneficial effects in preventing the progression of HF diet-induced cardiac 
 
and renal hypertrophy. With further research and human clinical trials, the possibility of using BM 
for the prevention of obesity-induced development of renal and cardiac pathophysiologies 
appears promising. 
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